Safety of Live Attenuated Influenza Vaccine in Children With Asthma.

ABSTRACT:

Background and objectives

Asthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged ≥5 years because of concerns for wheezing events. We evaluated the safety of LAIV4 in children with asthma, comparing the proportion of children with asthma exacerbations after LAIV4 or quadrivalent inactivated influenza vaccine (IIV4).

Methods

We enrolled 151 children with asthma, aged 5 to 17 years, during 2 influenza seasons. Participants were randomly assigned 1:1 to receive IIV4 or LAIV4 and monitored for asthma symptoms, exacerbations, changes in peak expiratory flow rate (PEFR), and changes in the asthma control test for 42 days after vaccination.

Results

We included 142 participants in the per-protocol analysis. Within 4

SUBMITTER: Sokolow AG 

PROVIDER: S-EPMC11235090 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature